Antibody–drug conjugates have emerged as ... stages that employ payloads with distinct mechanisms of action, from immune agonist payloads to protein degrader payloads and novel cytotoxic payloads.

This results in T reg cell depletion and a restored antitumor immune response ... optimized antibody–drug conjugates, to bispecific antibodies and chimeric antigen receptors for cell-based ...

CSPC Pharmaceutical Group Ltd.’s antibody-drug conjugate SYS-6045 has been granted clearance by China’s National Medical Products Administration (NMPA) to enter clinical trials in China for advanced ...

Elevation Oncology Inc. has nominated EO-1022 as its HER3 antibody-drug conjugate (ADC) development candidate for the treatment of solid tumors that express HER3. EO-1022 is currently advancing ...

An antibody-drug conjugate (ADC) targeting CD30 ... TNFRSF molecules and ligands are targeted on cells of the immune system to boost immune activity against a tumor cell or on tumor cells to ...

Enter the game-changer—two Pt-MSA-2 conjugates (I and II). These ingenious compounds bring together the DNA-damaging power of cisplatin and the immune-activating strength of STING agonist MSA-2.

Ltd. has exercised its exclusive option to acquire global development, manufacturing, and commercialization rights for an antibody-drug conjugate (ADC) from DualityBio, a collaborator of Nona ...

Ltd. The partnership will leverage MediLink's TMALIN antibody-drug conjugate (ADC) platform to develop a novel LRRC15 ADC, known as ZL-6201, which includes an antibody discovered by Zai Lab.